Diagnostic Metabolomic Profiling of COPD as Potential Biomarkers in Older and Younger Patients

COPD metabolomic biomarkers
Study identifies 10-metabolite panel distinguishing COPD from healthy subjects with ~90% accuracy, highlighting lipid metabolism dysregulation and offering new diagnostic insights.

Metabolomic biomarkers for COPD diagnosis across ages

Diagnostic gap and rationale for blood-based metabolomics in COPD

Currently, Chronic Obstructive Pulmonary Disease (COPD) has high levels of underdiagnosis (>60% in the United States and Europe) despite being the third leading cause of death worldwide. The analysis of blood metabolite composition can improve diagnostic accuracy and offer deeper insights into the molecular pathophysiology of COPD. Sadly, most of the studies lack including important emerging groups of patients (young COPD and women). In this study, plasma metabolomic profiling was conducted to identify disease-related metabolic biomarkers associated with COPD.

Implications and next steps in biomarker validation

We identified significantly altered metabolite profiles in COPD patients compared to healthy controls, highlighting specific metabolites that exhibited potential as discriminative biomarkers and providing novel insights into COPD pathogenesis. Future validation and mechanistic studies are still needed.

Authors

C.J. Enríquez Rodríguez, C. Casadevall, I. Abramovich, B. Agranovich, M.R. Faner, E. Barreiro, C. Casanova Macario, A. Castro-Acosta, B.G. Cosio, J. Garcia Aymerich, J.L. Lopez Campos, E. Monso, S. Pascual-Guardia, G. Peces-Barba, S. Santos, L. Seijo, J.J. Soler Cataluna, A. Agusti, E. Gottlieb, J. Gea, BIOMEPOC BIOEARLY

Read more details at

ATS Journals

Fecha de publicación

May 2025 (Publication date)

Categorías asociadas al artículo

Results:

Noticias relacionadas

Imagen desarrollada DALL·E y Canva

Etiquetado , , , , , , ,

Entérate de
Nuestras Publicaciones